Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2009 Oct;24(10):3151-7.
doi: 10.1093/ndt/gfp260. Epub 2009 May 27.

The association between parathyroid hormone and mortality in dialysis patients is modified by wasting

Christiane Drechsler  1 , Vera Krane, Diana C Grootendorst, Eberhard Ritz, Karl Winkler, Winfried März, Friedo Dekker, Christoph Wanner; German Diabetes and Dialysis Study Investigators
Affiliations

The association between parathyroid hormone and mortality in dialysis patients is modified by wasting

Christiane Drechsler et al. Nephrol Dial Transplant. 2009 Oct.

Abstract

Background: The association between parathyroid hormone (PTH) level and mortality in dialysis patients is controversial. We hypothesized that wasting, a common condition potentially related to adynamic bone disease, modifies the association of PTH with mortality and cardiovascular events (CVE), respectively.

Methods: We analysed data from 1255 diabetic haemodialysis patients, participating in the German Diabetes and Dialysis Study between 1998 and 2004. The patients were stratified by the presence or absence of wasting (albumin <or=3.8 versus albumin >3.8 g/dL; BMI <or=23 versus BMI >23 kg/m(2)). Using Cox regression analyses, we calculated the risks of (1) all-cause mortality and (2) CVE according to baseline PTH levels. All analyses were adjusted for age, sex, atorvastatin treatment, duration of dialysis, comorbidity, HbA1c, phosphate, calcium, blood pressure, haemoglobin and C-reactive protein.

Results: Patients had a mean age of 66 +/- 8 years, and 54% were male. Among patients without wasting (albumin >3.8 g/dL, n = 586), the risks of death and CVE during 4 years of follow-up significantly increased by 23% and 20% per unit increase in logPTH. Patients in the highest PTH tertile had a 74% higher risk of death (HR(adj) 1.74, 95% CI 1.27-2.40) and a 49% higher risk of CVE (HR(adj) 1.49, 95% CI 1.05-2.11) compared to patients in the lowest PTH tertile. In contrast, no effect was found in patients with wasting. Accordingly, additional analyses in strata of BMI showed that PTH significantly impacted on death and CVE [HR(logPTH)(adj) 1.15 and 1.14, respectively] only in patients without, but not in patients with, wasting.

Conclusions: Wasting modifies the association of PTH with adverse outcomes in diabetic dialysis patients. High PTH levels are of concern in the patients without wasting, while the effect of PTH on mortality is nullified in the patients with wasting.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Kaplan–Meier curves for the time to all-cause mortality in patients with wasting (albumin ≤3.8 g/dL, A) and patients without wasting (albumin >3.8 g/dL, B); patients were grouped into tertiles of parathyroid hormone levels with the lowest tertile (tertile 1) serving as the reference group.
See this image and copyright information in PMC

References

    1. Kronenberg HM, Brinkhurst FR, Nussbaum S, et al. Parathyroid hormone: biosynthesis, secretion, chemistry and action. In: Mundy GR, Martin TJ, editors. Handbook of Experimental Pharmacology of Bone. Heidelberg, Germany: Springer; 1993. pp. 185–201.
    1. Murray TM, Rao LG, Divieti P, et al. Parathyroid hormone secretion and action: evidence for discrete receptors for the carboxyl-terminal region and related biological actions of carboxyl- terminal ligands. Endocr Rev. 2005;26:78–113. - PubMed
    1. van Abel M, Hoenderop JG, Van Der Kemp AW, et al. Coordinated control of renal Ca(2+) transport proteins by parathyroid hormone. Kidney Int. 2005;68:1708–1721. - PubMed
    1. Hedback G, Oden A. Increased risk of death from primary hyperparathyroidism—an update. Eur J Clin Invest. 1998;28:271–276. - PubMed
    1. Nilsson IL, Yin L, Lundgren E, et al. Clinical presentation of primary hyperparathyroidism in Europe—nationwide cohort analysis on mortality from nonmalignant causes. J Bone Miner Res. 2002;17(Suppl 2):N68–N74. - PubMed

Publication types

Substances